Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views

Group 1 - Incyte reported adjusted earnings of $2.26 per share on $1.37 billion in third-quarter sales, falling short of analysts' expectations of $1.58 per share and $1.25 billion in sales [1] - The company's earnings in the same period last year were $1.07 per share on $1.14 billion in sales, indicating a year-over-year increase in earnings but a decline in sales compared to expectations [1] - Incyte raised its full-year sales guidance to between $4.23 billion and $4.32 billion, driven by higher demand for Jakafi and other products, although analysts projected earnings per share of $5.92 and sales of $4.84 billion [2] Group 2 - In premarket trading, Incyte's stock decreased by 1.7% to $91.50 following the earnings report [2] - The article mentions other companies experiencing stock movements, such as Viking and Sanofi, but does not provide specific financial details about them [3]